Author profile

Katharina Dobrovits ( Berlin)

Publications

Author of book chapters / database content

Harrisons Innere Medizin (19. Auflage)
- Resistenzmechanismen einiger Bakterien gegenüber AntibiotikaKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ChloramphenicolKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Perinatale CMV-InfektionenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- PolymyxineKatharina Dobrovits, Norbert SuttorpGo to this chapter
- MetabolismusKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Pathologie des ZytomegalievirusKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Ort der InfektionKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Pathogenese der ZytomegalievirusinfektionKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Unerwünschte Ereignisse unter BetalaktamenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- MupirocinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Quinupristin-DalfopristinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- NitrofurantoinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Weiterführende LiteraturKatharina Dobrovits, Norbert SuttorpGo to this chapter
- FosfomycinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- EliminationKatharina Dobrovits, Norbert SuttorpGo to this chapter
- NitrofurantoinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Hemmung der ZellwandsyntheseKatharina Dobrovits, Norbert SuttorpGo to this chapter
- CMV-MononukleoseKatharina Dobrovits, Norbert SuttorpGo to this chapter
- MupirocinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Tetrazykline und GlyzylzyklineKatharina Dobrovits, Norbert SuttorpGo to this chapter
- FluorchinoloneKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Hemmung des BakterienstoffwechselsKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Humanes Herpesvirus Typ 6, 7 und 8Katharina Dobrovits, Norbert SuttorpGo to this chapter
- CMV-Infektionen bei immungeschwächten PatientenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ChloramphenicolKatharina Dobrovits, Norbert SuttorpGo to this chapter
- PharmakodynamikKatharina Dobrovits, Norbert SuttorpGo to this chapter
- DaptomycinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- SulfonamideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Humanes Herpesvirus Typ 6 und 7Katharina Dobrovits, Norbert SuttorpGo to this chapter
- Makrolide und KetolideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- AminoglykosideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- AminoglykosideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Grundsätze der InfektionsprophylaxeKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Störung der Integrität der ZellmembranKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Prävention der ZytomegalievirusinfektionKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Klinischer Einsatz antibakterieller SubstanzenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Weiterführende LiteraturKatharina Dobrovits, Norbert SuttorpGo to this chapter
- GlykopeptideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- MetronidazolKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ChinoloneKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ZytomegalievirusKatharina Dobrovits, Norbert SuttorpGo to this chapter
- CephalosporineKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Pharmakokinetik von AntibiotikaKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ResorptionKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Makrolide und KetolideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Definition des ZytomegalievirusKatharina Dobrovits, Norbert SuttorpGo to this chapter
- DaptomycinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- StreptogramineKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Makrolide, Ketolide, Lincosamide und StreptogramineKatharina Dobrovits, Norbert SuttorpGo to this chapter
- OxazolidinoneKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ExpositionenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Grundsätze der AntibiotikatherapieKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Epidemiologie des ZytomegalievirusKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Behandlung: ZytomegalievirusinfektionKatharina Dobrovits, Norbert SuttorpGo to this chapter
- CarbapenemeKatharina Dobrovits, Norbert SuttorpGo to this chapter
- MetronidazolKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Hemmung der ProteinsyntheseKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ChinoloneKatharina Dobrovits, Norbert SuttorpGo to this chapter
- WirtsfaktorenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- OxazolidinoneKatharina Dobrovits, Norbert SuttorpGo to this chapter
- AminoglykosideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- TherapiedauerKatharina Dobrovits, Norbert SuttorpGo to this chapter
- TherapieversagenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Wirkungsmechanismen – ResistenzmechanismenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Trimethoprim-SulfamethoxazolKatharina Dobrovits, Norbert SuttorpGo to this chapter
- AllergienKatharina Dobrovits, Norbert SuttorpGo to this chapter
- GlykopeptideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Wirkungsmechanismen - Behandlung und Prophylaxe bakterieller InfektionenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Klinisches Bild der ZytomegalievirusinfektionKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ExpertenempfehlungenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- GlykopeptideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Kongenitale CMV-InfektionKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Abschnitt 12: Infektionen durch DNS-VirenStefan Mühlenbein, Michael Hertl, Felix Wagner, Florian Schlenk, Norbert Suttorp, Katharina Dobrovits, Holger Müller-Redetzky, Christoph Tabeling, Birgit KlagesGo to this chapter
- Diagnostik der ZytomegalievirusinfektionKatharina Dobrovits, Norbert SuttorpGo to this chapter
- BetalaktameKatharina Dobrovits, Norbert SuttorpGo to this chapter
- SchwangerschaftKatharina Dobrovits, Norbert SuttorpGo to this chapter
- RifamyzineKatharina Dobrovits, Norbert SuttorpGo to this chapter
- MetronidazolKatharina Dobrovits, Norbert SuttorpGo to this chapter
- 219 Zytomegalievirus und humanes Herpesvirus Typ 6, 7 und 8Katharina Dobrovits, Norbert SuttorpGo to this chapter
- Rationaler Einsatz von AntibiotikaKatharina Dobrovits, Norbert SuttorpGo to this chapter
- LipopeptideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Sulfonamide und TrimethoprimKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Penicilline und Betalaktamase-InhibitorenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Tetrazykline und GlyzylzyklineKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Teil 8: InfektionskrankheitenCaroline Isner, Norbert Suttorp, Stefan Hippenstiel, Katrin Gentil, Trinad Chakraborty, Mariana Schürmann, Michael Glas, Miriam Songa Stegemann, Thomas Back, Felix Stelter, Frieder Pfäfflin, Alexander Uhrig, Vincent van Laak, Mathias Pletz, Hartwig Schütte, Jessica Rademacher, Joachim Seybold, Julia Pickert, Michael Hertl, Heiner Appel, Lars Esmann, Verena Moos, Thomas Schneider, Christian Höfling, Dirk Fahlenkamp, Charlotte Keller, Andreas Jödicke, Olaf Hoffmann, Ulrike Möbius, Marie Charlotte von Heinz, Christoph Ruwwe-Glösenkamp, Katharina Dobrovits, Andreas C. Hocke, Martin Witzenrath, Yaosi Li, Michaela Niebank, Birgit Klages, Nikolai Menner, Moritz Hilbrandt, Hazem A. Juratli, Lea Drobbe, Tilman Lingscheid, Matthias Raspe, Thomas Schneider, Kirsten Pörtner, Thomas Zoller, Bettina Temmesfeld-Wollbrück, Florian Steiner, Katharina Edle von Schmädel, Bodo Hoffmeister, Tim Andermann, Michael Benzke, Tamar Zhamurashvili, Stefan Mühlenbein, Felix Wagner, Florian Schlenk, Holger Müller-Redetzky, Christoph Tabeling, Muna Abu Sin, Dirk Schürmann, Matthias Paland, Katrin Moira Heim, Susanne Georgi, Jan-Moritz Doehn, Wiebke Düttmann, Florian Alius, Julian Tristan Schwartze, Florian Kurth, Carmen Garcia, Tobias Welte, Markus VogtmannGo to this chapter
- BetalaktameKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Pharmakokinetik und PharmakodynamikKatharina Dobrovits, Norbert SuttorpGo to this chapter
- LincosamideKatharina Dobrovits, Norbert SuttorpGo to this chapter
- TrimethoprimKatharina Dobrovits, Norbert SuttorpGo to this chapter
- PolymyxineKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Hemmung der DNS- und RNS-Synthese oder -AktivitätKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ClindamycinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- BetalaktameKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Empirische und gezielte TherapieKatharina Dobrovits, Norbert SuttorpGo to this chapter
- ChloramphenicolKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Bacitracin (topische Anwendung) und FosfomycinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- NitrofurantoinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Rifampicin und RifabutinKatharina Dobrovits, Norbert SuttorpGo to this chapter
- 170 Behandlung und Prophylaxe bakterieller InfektionenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- HHV Typ 8Katharina Dobrovits, Norbert SuttorpGo to this chapter
- Abschnitt 4: Therapie bakterieller ErkrankungenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Wechselwirkungen mit anderen MedikamentenKatharina Dobrovits, Norbert SuttorpGo to this chapter
- DistributionKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Tetrazykline und GlyzylzyklineKatharina Dobrovits, Norbert SuttorpGo to this chapter
- Sonstige WirtsfaktorenKatharina Dobrovits, Norbert SuttorpGo to this chapter